Featured Posts
Blog
Trump administration decision highlights disastrous Part D redesign
The Trump administration recently announced the end of a demonstration project that was pulled together by the Biden administration as the Inflation Reduction…
Study
A Free Market is the Best Medicine
Introduction The pharmaceutical supply market is seeing extraordinarily high levels of innovation and consumer-benefiting evolution. The combination of a competitive market for generic drugs,…
Blog
Congress considers micromanaging PBM finances
With the first reconciliation bill behind it, Congress is now looking to reform other aspects of the health care system. Pharmacy Benefit Manager…
Search Posts
USA Today
FDA rules won’t do much good
Food-borne illnesses kill as many as 3,000 Americans each year, but consumers should not expect new Food and Drug Administration regulations to help. These rules,…
Real Clear Policy
More FDA Control Does Not Mean More Safety
News outlets are reporting that the U.S. Food and Drug Administration (FDA) has cited an alarmingly high number of alleged safety and regulatory violations by…
Real Clear Markets
Global Governments’ Growing Embrace of Big Pharma
As the pharmaceutical industry wrestles with multiple existential threats-from price controls to patent cliffs to dwindling pipelines-calls are growing for deeper government-industry cooperation. As private…
Washington Times
High Price of Cheap Drug Imports
With the Senate set to vote on one of the few “must-pass” bills of the year, pharmaceutical industry critics are plotting ways to add poison…
Washington Times
ObamaCare’s Killer Device Tax
Much of the political conversation in Washington these days concerns innovation, job creation and competitiveness. But talk is cheap, and elected officials must enact policies…
Washington Times
The Off-Label Drug War of Words
If knowledge is power and ignorance is bliss, what is power used to prevent knowledge from eliminating ignorance? I don’t know; ask the FDA (U.S.